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THE LINC COMES HOME
In the early 1960s, digital computers were massive
and expensive. Far biomedical researchers, the
computers were neither accessible nor compatible
with their scientific needs. A group at Massachusetts
Institute of Technology's (MIT's) Lincoln Laboratory
set out to build an all-purpose, inexpensive, researchfriendly module. The National Institutes of Health
(NIH) recognized MIT's design as an important
research tool and encouraged research teams nationwide to submit proposals for projects to evaluate the
Laboratory Instrument Computer (LINC, as MIT's
design was called) as a lab tool. In all, 12 grants—
which included funds to build a LINC—were awarded;
Washington University in St. Louis was among
the recipients.
Eventually, as technology evolved and computers
became smaller, faster, and less expensive, LINCs
were phased out, often relegated to the trash heap.
Of the 50 LINC machines eventually built, only a
handful survived—and one of them is being restored
and will be permanently displayed at the Washington
University Medical Center.
Photographs by Kimberly Kania.
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4 Let there be...bioluminescence

Scientists in the Molecular Imaging
Center have a new way to identify
cell inflammation before a tumor
forms—that old crime-scene
standby, luminal, and its reaction
to an immune system bleach.
8 Unlocking the secrets of
Alzheimer's disease
28

FYI

Nuclear medicine physicians are
using positron emission tomography in several collaborative studies
to detect Alzheimer's disease before
the onset of cognitive symptoms.
14 Imaging the behavior of
cancer cells

>CHOOL OF MEDICINE
IJ Mallinckrodt Institute
'"adiology

Visit the MIR web site at
www.mir.wustl.edu

Researchers in MIR's Radiological
Chemistry Lab have developed a
new approach—positron emission
tomography and sigma-2 receptors—
to directly visualize the behavior of
cancer cells.

18 CRMO—imaging is key to
accurate diagnosis

Multimodality imaging is helping to
diagnose and assess chronic recurrent multifocal osteomyelitis, an
autoinflammatory disease affecting
children and young adults.
A paradoxical view of cancer

Collaborative research has made a
marked contribution to the cure of
advanced breast cancer—a novel
way of assessing the best treatment
for patients who have exhausted
most available therapies.

ON THE COVER Robert Much, PhD, is in the Institute's cyclotron facility, where radiotracers are produced for use in PET imaging of solid tumor cell
proliferation. Photograph by Tim Parker.
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In the 2009 U.S. News & World Report rankings
of graduate and professional programs, Washington University School of Medicine was named
third among the country's top 10 research-oriented medical schools—tied with the University of
Pennsylvania. The top spot went to Harvard University, second to Johns Hopkins University. The
University of California, San Francisco was ranked fifth, with Duke University, Stanford University, the University of Washington, and Yale University tied for sixth place. For the eleventh consecutive year, WUSM was named number one in student selectivity (based on college grade-point
averages and MCAT scores).

Bhalla

lecture

Sanjeev Bhalla, MD, associate professor of radiology and chief of Cardiothoracic
Imaging, was selected by the Washington University School of Medicine students as the
56"' Annual Alpha Omega Alpha lecturer. He holds the honor of being one of two faculty
members to have been selected twice as lecturer. Bhalla presented "Lights along the path:
getting the most education in residency."
The Alpha Omega Alpha Honor Society, established 107 years ago at the College of
Physicians and Surgeons in Chicago, is considered the most prestigious honor society in
the medical profession and has more than 50,000 members nationally. The Washington
University chapter was organized in 1905.

9

fy Alpha Omega

41st Wilson
Award
presented
Following Washington University's 148°'
Commencement ceremony
in May, Lauren Qing
Chang Sen received the
2009 Hugh M. Wilson
Award for Meritorious
Work in Radiology. Sen,
a fourth-year medical student, was mentored by
Jay Heiken, MD, professor
of radiology and chief of
Abdominal Imaging. The
annual Wilson Award
honors Mallinckrodt
Institute's second director,
an advocate of the
advancement of education.

Honor Medica
founded 1 902

Worthy to Serve the Suffering

CMS expands coverage for PET
The Centers for
Medicare & Medicaid
Services (CMS) announced
in April that it would cover
costs for positron emission
tomography (PET) scans
used to support initial diagnosis and treatment for most
solid tumor cancers. CMS
also expanded coverage for
the use of PET scans for
follow-up testing for cervical

and ovarian cancer and
myeloma. Eight other types
of cancer continue to be
covered: breast, colorectal,
esophageal, head and neck,
lymphoma, melanoma, nonsmall cell lung, and thyroid.
Follow-up testing of all other
cancers continues under the
CMS coverage with evidence
development (CED) policy.

The CMS decision was
fueled by clinical results of
the NOPR (National Oncologic PET Registry) study,
a nationwide CED effort
that helped to prove the
effectiveness of PET in diagnosing, staging, restaging,
and monitoring treatment
for many cancers. Sponsored
by the Academy of Molecular
Imaging and managed by
the American College of
Radiology (ACR) and the

ACR Imaging Network, the
NOPR began accruing
patients in May 2006.
Mallinckrodt Institute's Bar'
Siegel, MD, a key advocate
for and organizer of the
NOPR, serves as cochair of
the NOPR working group.
To read more about this
expanded coverage, go to
www.cms.hhs.gov. In the
search box, type "PET
coverage for cancer."

MALLINCKRODT INSTITUTE OF RADIOLOGY

Street earns RSNA R&E award
Mandie Street, AERT,
clinical research coordinator,
received a Radiological Society of North America (RSNA)
Research and Education
Foundation award for her
project "Using six sigma

techniques to reduce radiation dose," which will assess
progress in optimizing radiation exposure during pedatric
fluoroscopy procedures. The
award of up to $10,000 is
sponsored by the Association
of University Radiologists,

the Association of Program
Directors in Radiology, and
the Society of Chairmen of
Academic Radiology Departments. James Duncan, MD,
PhD, associate professor of
radiology, serves as Street's
mentor for the project.

Welch corecipient of cancer fund grant

I

I

Michael Welch, PhD, professor of radiology, of chemistry, and of molecular
biology and pharmacology, and John-Stephen Taylor, PhD, professor of chemistry,
received the first research grant awarded by the Kay Yow/Women's Basketball
Coaches Association (WBCA) Cancer Fund and the V Foundation for Cancer
Research. The
$100,000 award will
fund the Siteman
Cancer Center
research project
"Targeted nanoparticles optimized for
breast cancer diagnosis and therapy."
The award was
presented during
the NCAA Women's
Final Four weekend in St. Louis.
Kay Yow,
North Carolina
State University
women's basketball
coach and breast
cancer patient who
(left to right) Michael Welch, PhD; Sue Donohoe, vice president, NCAA Division 1
died recently, creWomen's Basketball; John-Stephen Taylor, PhD; Marsha Sharp, president, Kay Yow/
ated the Kay Yow/
WBCA Cancer Fund; Nick Valvano, CEO, the V Foundation. Photo by Ray Marklin.
WBCA Cancer
Fund in 2007 to
fund research of women's cancers and to assist underserved women. The V Foundation for Cancer Research was established in 1993 by ESPN and the late Jim Valvano,
North Carolina State University basketball coach and ESPN commentator.
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Faculty receive
honors
Maurizio Corbetta, MD,
professor of neurology, of
radiology, and of anatomy
and neurobiology, was one
of five recipients of the
Washington University
School of Medicine Distinguished Investigator Award.
The award is among the
Distinguished Faculty
Awards presented annually
to recognize outstanding
achievements in clinical
care, community service,
research, and teaching.
Emily Smith, MD, assistant professor of radiology,
was one of two honorees
who received the WUSM
Alumni/Faculty award. She
earned a WUSM medical
degree in 1968 and completed
a diagnostic radiology residency in 1972. In addition to
serving on the Mallinckrodt
Institute faculty for the past
35 years, Smith is an Eliot
Society Patron and has
chaired the WUSM Annual
Fund for 11 years.
Pamela Woodard, MD,
associate professor of radiology and cohead of Cardiac
CT/MR, was elected a fellow
of the American College of
Radiology (ACR), one of the
highest honors ACR can
bestow on a radiologist,
radiation oncologist, or
medical physicist. The convocation ceremony was in
May at the ACR's 86th
Annual Meeting and Chapter
Leadership Conference.

LET THERE BE...-,

On summer nights,

Perfecting
an imaging

• children chase after fireflies, trying to capture these fascinating

technique

insects that generate their own blinks of light.

that sheds

Then there's David Piwnica-Worms, MD, PhD, professor of

new light

, radiology and of developmental biology. He exploits firefly-like

on diseases

chemistry to capture glowing images of disease in living mice.

and their

What he's seen lately on his computer screen leaves him as

treatment

astonished as a child.
A molecule called luminol—cousin to light-producing luciferin

by Robert Lowes
in fireflies—shines blue when it reacts with an immune-system

I

bleach that causes tissue inflammation. Using this type of
bioluminescence, Piwnica-Worms and his research team have
spotted the subtlest beginnings of inflammation in the tail of a
mouse—not

detectable by sight or palpation—only to watch it

morph into a tumor four weeks later. "We were amazed that we
>

could show inflammation starting long before the tumor formed,"
says Piwnica-Worms, director of the Molecular Imaging Center
(MIC) at Washington University.

,

His team published its findings
on bioluminescence imaging of
inflammation earlier this year in
the journal Nature Medicine. It
marked the latest development in a
molecular imaging technique that
Piwnica-Worms has honed over the
past 10 years, a technique that in
some applications could someday
outshine such stalwarts as magnetic resonance imaging (MRI).
With every new finding, PiwnicaWorms demonstrates the versatility
of bioluminescence imaging, which
is already helping to develop new
drugs and may someday spot
potential blood clots and even
guide the hand of cancer surgeons.
When bleach is spilled

Piwnica-Worms has literally
taken his scientific cues from the
humble firefly. In earlier research
projects, he and his team extracted
the firefly gene that makes an
enzyme called luciferase and introduced it into lab mice, often in the
role of a "reporter" gene. They
once added the gene to the DNA of
a strain of mice so the animals could
make their own luciferase. The mice
were then injected with a common
cold virus that was genetically
engineered to turn on the luciferase
gene. The mice also received a dose
of luciferin, a firefly compound
that glows when it encounters
luciferase. When investigators put
the live mice under a special
camera in a light-free box, they
could identify tissues infected by
the virus, since it triggered the
production of luciferase wherever
it spread, and the luciferase, in
turn, reacted with the luciferin.
MIC researchers have used this
luciferase-luciferin combo in other
ways to illuminate gene expression
and protein function in disease
processes. As a result, they've
learned how to use this form of
bioluminescence to screen various
compounds for drug candidates
and to test the efficacy of experimental drugs in mice.
FOCAL SPOT, SPRING 2009

The experiment
described in Nature
Medicine achieved
bioluminescence
with luminol, a
man-made version
of luciferin. It's the
ingredient that
makes glow sticks
glow, but luminal is
put to a gruesome
task in law enforcement. Because it
reacts with blood to
produce a blue
light, detectives
routinely spray
crime scenes with a
solution containing
luminol and hydrogen peroxide to
detect blood stains
that otherwise
might escape
notice. Medical
detectives have
Robin Dothager, PhD, post doctoral research associate, and (le(t) David Piwnicaturned to luminol
Worms, MD, PhD, are in the bioluminescence imaging room. The black box takes
as well, in part
images of photons emitted by mice; that data is then fed into computers for analysis.
because it appears
to be safe to use in human experiand that's what contributes to
ments, although further research is
inflammation at its destructive
needed to bear that out.
worst. " You have a big battle that
The focus of the Nature Medicine
gets out of control," says Piwnicastudy was myeloperoxidase, or MPO,
Worms. "The neutrophils and
a key protein found in two immune
macrophages are spilling bleach on
cells called neutrophils and
the body's own tissues."
macrophages. Such cells are proMPO catalyzes other loose
grammed to swallow an intruder
cannon molecules such as tyrosyl
such as a bacterium, enclose it in
radicals that damage invader and
a sack-like structure called a phagohost alike. This havoc isn't good,
some, and inject the phagosome
because inflammation is a precurwith MPO and hydrogen peroxide.
sor to a wide variety of disorders
The MPO then produces hypochlorlinked to the immune system—
ous acid to destroy the cocooned
rheumatoid arthritis, atherosclerosis,
invader. "Hypochlorous acid is basirenal glomerular injury, pulmonary
cally a type of bleach, and bleach is
fibrosis, Alzheimer's disease,
a great antiseptic," says PiwnicaParkinson's disease, and certain
Worms, the study's senior author.
cancers. So analyzing the bleach
The bleach helps mice as well
production of MPO has enormous
as humans stave off bodily insults,
potential for studying and treating
but during an autoimmune
these diseases.
response, it doesn't necessarily
stay confined to the phagosomes

■
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bioluminescence

Earlier studies at other
research centers have observed
luminal-bioluminescence in
MPO-produced hypochlorous
acid in test tube experiments and
extracted whole blood. Shimon
Gross, PhD, lead author of the
Nature Medicine article and a
former post-doctoral fellow in
the MIC, wanted to see if luminol
would shine when it penetrated
the phagosomes of immune cells
in living animals and reacted with
bleach there. Enter the lab mice.
"Gene-knockout" mice prove
a point

The luminol experiment involved
two sets of mice. One set was normal, as mice go. The other group
was genetically engineered so that
the gene responsible for creating
MPO was turned off. In other
words, neutrophils and macrophages
in these "gene-knockout" mice
couldn't manufacture hypochlorous
acid. Thus, if MPO was the primary
source of the observed bioluminescence, then the MPO gene-knock-out
mice should not glow.
Both sets of mice had the same
disorders involving inflammation.
Some had dermatitis, others had
arthritic ankles. Still others were
genetically engineered so they
were prone to develop tumors,
often at the site of a bite or scratch.
MIC researchers took bioluminescent snapshots of them on a daily
or weekly basis, depending on the
disorder. Each imaging session was
preceded by a luminol injection.
Piwnica-Worms was gratified
to see the blue glow of scientific
confirmation. Bioluminescence
imaging detected inflammation in
normal mice, but not in those lacking
MPO. What caused the bioluminescence in particular was the highly
concentrated bleach inside the
phagosomes of immune cells. In
contrast, hardly any bioluminescence
materialized in conjunction with

Kelly Flentie, graduate research assistant, and
Piwnica-Worms in the Cell Biology Lab.

eosinophil peroxidase, or EPO, a
protein similar to MPO that's found
in immune cells called eosinophils.
EPO creates its own weapon—
hypobromous acid—to destroy
microscopic trespassers, and while
this acid makes luminol glow in a
test tube, it didn't do that in vivo in
the MIC experiment. Because
eosinophils squirt their acid at foreign bodies without first engulfing
them, "the relative concentration
of the reactants is too low to elicit
significant bioluminescence,"
notes Gross.
Vivo in vivo
The MIC research on luminolbioluminescence underlines the
value of diagnostic imaging that
can monitor the course of disease
in vivo and noninvasively over
weeks and months. That doesn't
happen with traditional ex vivo

research techniques, explains
Piwnica-Worms. "You'd sacrifice a
mouse to study inflammation in a
tissue sample, for example, but
you'd never know whether that
inflammation would lead to cancer
two months later."
By eliminating the need to
continually sacrifice lab mice, in
vivo imaging allows investigators
to use fewer of them, reducing
costs. In addition, statistical results
are tighter, he says. "Each mouse
is compared to itself over time."
Other imaging techniques can
monitor diseases processes in vivo,
but luminol-bioluminescence outperforms them in several respects.
One advantage is greater sensitivity
to low-level inflammation as measured by signal-to-noise ratio. In
bioluminescence images of one
type of tissue inflammation
described in the Nature Medicine
study, this ratio exceeded 3000.

MALLINCKRODT INSTITUTE OF RADIOLOGY
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When MRI and single photon
emission computed tomography
(SPECT, a nuclear medicine imagng
technique based on gamma rays)
were used, it
dropped to 1.7 and
2.6, respectively.
Due to its relative
simplicity, luminolbioluminescence
imaging also is a
speedier way to
obtain biological
images. "We can
process two
hundred mice in a
single afternoon to
fully characterize a
Shimon Gross, PhD
biochemical or drug
action," says
Piwnica-Worms. "We are fans of
all modalities, but MRI and PET
!
[positron emission tomography]
are limited by their throughput
rate. It's a great day if we get four
mice done."
Luminol-bioluminescence
imaging, as it stands now, has one
significant disadvantage that would
hamper any future application
with human
subjects—it
can't see very
deep inside the
human anatomy.
The light emitted by luminol
can only travel
up to one centimeter or so
before it's
absorbed by
tissues and
rendered
undetectable.
Imaging arthritis with
luminol-bioluminescence
imaging.

10 photons s
-2 -1
cm sr

1
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Consequently, the technique currently would work just for the skin,
and tissues and blood vessels near
the surface, such as the carotid
arteries. In contrast, MRI, SPECT,
and PET probe the entire body.
However, Piwnica-Worms says
it's possible to take bioluminescence imaging deeper by attaching
the necessary fiber-optic tip to a
scope. "You could snake the scope
inside arteries, the colon, or the
lungs," he says. He's also hoping to
redesign the luminol molecule so
that it emits not a blue light, but
a red one. Due to its longer wavelength, a red light could travel two
or even three centimeters before
being absorbed by the body.
No cancer left behind?

For Piwnica-Worms, a little
bioluminescence goes a long way.
Every new discovery invariably
suggests a dozen more experiments.
"Sometimes you have more ideas than
hands to execute them," he jokes.
The recent findings on MPO
and inflammation are no exception
to the rule. He sees numerous possibilities for basic bench research.
"With genetic engineering,
you could remove the MPO from
neutrophils but retain it in
macrophages—or vice versa—
and study their exact roles in the
immune system," says PiwnicaWorms. "You might be able to
determine which cell is dominant
in specific diseases processes."
Luminol-bioluminescence also
promises to report on the efficacy
of experimental drugs—exactly
when they begin to reduce inflammation, and what dosages and
intervals work best. "The technique
gives us a new metric," he says.

Someday, clinicians may study
pictures of lit-up tissue to guide
treatment of their patients. Take
plaque buildup in the
carotid artery, for
example. "Not all
plaques are alike,"
says Piwnica-Worms.
"Some are what we
call active plaques,
because they contain
activated neutrophils
and macrophages that
are making bleach. As
compared to inactive
plaques, they're more
likely to become
thicker, form a
complete clot, and
cause a stroke.
Bioluminescence
could tell us whether
a carotid plaque is
active or not."
Likewise, luminolbioluminescence may
eventually help cancer
surgeons figure out
where they should
make an incision
with their scalpel.
D through G: large granular
"Certain cancers
lymphocytic tumor in mice,
cause inflammation
in surrounding tissues," showing colocalization of
luminol bioluminescence
says Piwnica-Worms.
with small tumor ioci
"Bioluminescence
(yellow arrows).
imaging could help
physicians to visualize
the inflammation and get a better
idea about the tumor's margins.
They'd be less likely to leave any
cancer behind."
All of this, of course, is scientific
speculation, but Piwnica-Worms
and his research team have been
converting speculation about
bioluminescence imaging into a
growing body of knowledge. So
he continues chasing after the
luminous evidence, out there like
a cloud of fireflies. EE3
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UNLOCKING THE SECRETS OF

r ELI Alzheimer's
IMAGING disease
by Candace O'Connor

For years, physicians made the official diagnosis of Alzheimer's
disease (AD) in the pathology laboratory, after a patient had died.
Imaging methods simply did not work in living patients. While
high-resolution magnetic resonance imaging (MRI) detected many
other diseases in the brain, it could not firmly indicate AD.
"Then something happened that surprised a lot of people,"
says Mark Mintun, MD, professor of radiology and of psychiatry.
The ability to image amyloid plaques, a hallmark brain lesion of
AD, dramatically changed that landscape — and PET [positron
emission tomography] has made that possible."
Mintun and his team are using PET, combined with exciting
new radioactive tracers, in a series of studies all focused on one
aspect of the disease: how to detect AD in its earliest stages before
cognitive symptoms have become evident. Even then, amyloid
plaques (the sticky protein deposits that are implicated in the
development of the disease) have begun to form in the brain, but
the patient shows no outward signs of illness.

we could identify
the pathology of
Alzheimer's disease
in someone's brain
before symptoms
occur, that would
mean that we could
diagnose—and potentially treat—
the disease before many brain cells
had died," says Mintun. "Multiple
treatments are being tested for
their ability to alter these amyloid
plaques. But right now, no one gets
these experimental drugs unless they
are showing quite a few symptoms."
In doing this research, Mintun
and his team are working with a
number of groups at Washington
University, especially the Alzheimer's
Disease Research Center (ADRC),
internationally renowned for its
clinical evaluation of patients with
AD. They also have strong ties to
basic researchers such as David

"We hope that PET can
continue to be a bridge
between the biochemical
hypotheses and all the great
ideas generated in a lab
such as David Holtzman's,
and test them in the rigorous research environment
of John Morris [professor of
neurology]," says Mintun.
"It's a marriage made in
heaven."

Imaging preclinical
disease
Already, scientists know
that AD, especially at onset,
progresses very slowly. But
once it starts, it is implacable, killing brain cells and
eventually causing a host of
cognitive symptoms such as
memory loss, poor judgment and

"We hope that PET can continue to be a bridge
between the biochemical hypotheses and all the
great ideas generated in a lab"
Holtzman, MD, professor of neurology and a world leader in defining
biochemical changes that characterize the onset of the disease.
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disorientation. The incidence of AD
increases rapidly with age, rising to
some 40 to 50 percent of the 80year-old population.
Through earlier PET studies,
researchers also know something
else: that 25 to 30 percent of people
aged 70 and older have some amyloid plaques in their brains. But
researchers don't know whether
the presence of these plaques
means that a patient will inevitably
develop AD.

Mintun in the PET/CT control room in the Center for
Clinical Imaging Research.

"We predict that people with
amyloid plaques have a higher risk
of developing Alzheimer's disease,
and the people without plaques
have a lower risk," says Mintun.
"Now we are hoping to see over
time whether that is true."
In a 2006 study, published in
the journal Neurology, Mintun and
nine colleagues took a first step
toward making that determination.
They tested 41 subjects without
dementia, using PET together with
an imaging tracer (developed in
2005 at the University of Pittsburgh)
called "Pittsburgh Compound-B" or
"PIB." When it was injected into a
vein, PIB circulated into the brain,
sticking to amyloid plaques.
Researchers could then see the
plaques on PET scans.

UNLOCKING THE SECRETS

Of

PET Alzheimer's
IMAGING disease

But that research led to further
questions: Over time, would these
plaques continue to develop? More
importantly, while most patients
with plaques will likely develop AD,
is there a subgroup that remains
free of dementia?
In new studies, funded primarily
by the National Institutes of Health
and by the ADRC, Mintun and others
are exploring these questions.
With the ADRC, they are identifying
more than a hundred subjects aged
65 and older who show no evidence
of dementia. Using PIB made in
Mallinckrodt Institute's Radiological Chemistry Lab, they will scan
each volunteer annually, and every

year the ADRC will conduct the
dementia evaluation.
Volunteers are not told
whether they have plaques, and
since the results are all coded, no
examining physician knows either.
"If you were told you have plaques
that may cause Alzheimer's disease,
you might start doubting yourself,"
says Mintun. "Am I remembering
correctly? Maybe I'm losing my
memory. It's much better if it's
a blind study."
Researchers hope to attract as
many volunteers as possible and
then to observe them for five to 10
years, tracking which ones develop
AD and correlating those findings

Rows of color images are PET scans of a volunteer who received an injection of Cl 1 -labeled PIB. Shown are horizontal slices of the brain, from the bottom of the brain (left) to
the top (right). Each PET scan is matched to MRI images (black-and-white rows beneath each colored PET scan) of the same person. Top row: a volunteer with dementia of the
Alzheimer's type (DAT) has high uptake (indicated by red and yellow) because of binding of the PIB to amyloid plaques. Third row: PET scan of volunteer who is cognitively normal has only background levels of PIB in the brain.

with plaque development. Perhaps
they will discover, says Mintun,
that 100 percent of those with
plaques eventually develop the
disease. But if 80 percent of those
with plaques get the disease while
20 percent do not, that leads to
other intriguing questions.
"Do these people have a
different diet? Are they on some
medication, maybe for cholesterol?
Is it because they do crossword
puzzles or exercise? Is it because
they don't have diabetes or heart
disease?"asks Mintun. "What are
the reasons why someone would
develop these plaques in the brain
and yet seem to hold off Alzheimer's
disease for a long time?"
More than 20 new treatments
aimed at clearing these plaques or
preventing them from developing
in the first place are currently
wending their way though clinical
trials. Not only must pharmaceutical
companies test the drugs' efficacy,
but they also have to ensure that
patients don't experience intolerable
adverse effects. Still, says Mintun,
there is strong hope that effective
new drugs are on the horizon.
Ideally, he says, physicians
would like to stop the disease in its
tracks before— not after—memory
loss and other symptoms have
occurred. So this study is of
immense importance to the future
treatment of AD.
"I use the analogy of someone
who has heart disease, with
plaques in the coronary arteries,"
says Mintun. "All of a sudden that
person has a heart attack that
causes permanent muscle damage;
at that point, if the plaques are
removed, it won't reverse the damage. Amyloid in the brain may be

FOCAL SPOT, SPRING

In the Radiological Chemistry Lab, Greg Gaehle is
setting up a carbon-11 PIB synthesis study.

kicking off a series of events that
cause the brain cells to die After
they begin dying, removing the
amyloid might not be as helpful as
if you could start the process earlier.

Looking at the
hippocampus
While amyloid plaques
are one problem in the
brains of patients with AD,
researchers are also investigating whether there are
others. Mintun is working with
a Washington University group
led by Denise Head, PhD, assistant
professor of psychology, to examine the hippocampus, a highly sensitive part of the brain associated
with memory and emotions. It
appears that in patients with AD,
the hippocampus loses cells and
begins to shrink as part of the
disease process.
"So Doctor Head argued that
if people with amyloid plaques
develop the disease so early that
you can't clinically see it, maybe
they also had very early loss in the
hippocampus," says Mintun. "It
turns out that these patients have
a normal hippocampus volume,
but they are in the low end of the
normal range and significantly dif-

Hippocampus

ferent from people lacking plaques.
Further, their hippocampus volume
is going down every year."
This downward trend tallies
with the results of cognitive testing
done by Martha Storandt, PhD, professor of psychology, on patients
who are amyloid-positive and those
who are amyloid-negative, as identified through +PIB/PET. Among
those who are PIB-positive, their
cognition—though still within the
normal range—is trending slowly
downward year by year. People
without plaques varied slightly, but
overall their cognition held steady.

m
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PET Alzheimer's
IMAGING disease

Some brain regions may show amyloid plaques earlier than others. Right: an average of PIB PET scans of volunteers who were cognitively normal; scans created by subtracting background activity, left: correlating average MR
image to show anatomy. When processed in this way, PET image shows in stark contrast specific areas of brain
(outlined in red) that have subtle, but abnormal, amyloid binding of PIB. Identification of such brain regions may
help to increase sensitivity in detecting amyloid plaques in the earliest stage.
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The hippocampus is also
closely linked to other parts of the
brain through neural networks.
Yvette Sheline, MD, professor of
psychiatry, also working with
Mintun, decided to see whether the
interaction of the hippocampus
with these areas (its "functional
connectivity") is impaired in people
with symptoms. Using a functional
MRI method developed by Marcus
Raichle, MD, professor of radiology
and of neurology, and chief of the
Institute's Neuroimaging Lab, they
have been studying the "resting
state connectivity" of the brain in
patients with AD and in people with
no cognitive impairment. Not surprisingly, the people with AD showed
vastly different connectivity from
those who did not have the disease.
Using PIB and PET, they have
taken that latter group of nonimpaired people and separated
them into those with plaques and
those without. Now they are testing
each of these groups using functional MRI to see whether there are
connectivity differences. "And sure
enough," says Mintun, "they had a
subtle but very clear decrease in
the connectivity of their hippocampus to other areas of their brain."
All of these signals—decreasing
cognition, a shrinking hippocampus
and deteriorating functional connectivity—may eventually help
researchers to establish whether
the disease has begun and how far
it has progressed. They will also
help physicians decide who would
most benefit from medication, thus
sparing those who do not yet need
it from the possible adverse effects
of powerful drugs.

*
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Brain Inflammation
Researchers hypothesize that
one of the first things to happen in
the AD process is the deposition of
amyloid plaques in the brain. Then,
years later, neurons begin to die.
What causes them to die—and why
such a long delay? A possible
culprit is brain inflammation, and
controlling it may be a critical component of helping people with AD.
In a new project, Mintun and
his group are partnering with
Robert Mach, PhD, head of the
Institute's Radiological Chemistry
Lab, to develop better ways of
imaging brain inflammation. Mach
is trying to produce a new tracer
that would bind to the inflamed
cells, which would then show up
on PET imaging. Though he is
building on the foundation of a
tracer developed several years ago,

"We would like to develop a
technique sensitive enough to see
the types of inflammation that
occur in Alzheimer's disease and
then monitor them," says Mintun.
"Does it correlate with the severity
of the symptoms or with the
number of amyloid plaques in the
patient's brain? Is the inflammation
different from one person to
another? Does it track with how
quickly the cognitive abilities are
declining? These are all questions
that are difficult to answer without
an imaging tool."

Looking to the Future

that major advances will take place
within this generation. So many
researchers are tackling these
problems, from so many directions,
that there is a far better understanding now of the mechanism of
this terrible disease. And clinical
treatments cannot come soon
enough, he says, given the suffering
of patients with AD and their families.
Mintun illustrates the severity
of AD with an anecdote from a presentation he was giving with John
Morris: "Doctor Morris asked a
room full of people aged fifty and
older, 'How many people here have

As researchers move further
into this new realm of experimentation, it is clear that PET provides
information that other methods
cannot. Using molecular imaging, it
can use trace amounts of molecules, noninvasively, to supply

Researchers hypothesize that one of the first
[things to happen in the AD process is the
deposition of amyloid plaques in the brain...
Mach has a difficult task ahead.
The existing tracer binds only
weakly to inflamed cells, so the
resulting PET signal is not strong
enough. Ideally, Mach hopes to
develop one that is 10 times
stronger, but still binds firmly
to its targets. First, he will test
proposed compounds in mice,
and then in humans.
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unique feedback on biochemical
and cellular processes in the
human brain. And Mallinckrodt
Institute is perfectly positioned to
do this PET imaging, with its
history as the place where PET
was developed and its record of
"firsts" in the field, says Mintun,
who heads the Center for Clinical
Imaging Research.
While it is impossible to
predict when clinical breakthroughs may occur, Mintun and
his colleagues remain optimistic

survived cancer?' Hands went up.
When he asked about heart attacks,
again a lot of hands went up,"
says Mintun. "But when he asked
how many had survived Alzheimer's
disease, no hands were raised. AD
is a relentless disease, one-hundred
percent fatal. I am cautiously
optimistic, but we are not there
yet—and a lot of people
are suffering." Pm

IpTJAMrFirfTjA
by Amy Thomas, MD, FAAP

ancer treatment has come a long way but, as
most would agree, not far enough. Cytotoxic
chemotherapy, which works by damaging divided
cancer cells and preventing their reproduction,
has been around for nearly 60 years.
More recently, targeted therapies

of cancer treatment. While PET is

that preferentially bind certain

effective at staging cancers and

cancer cells have emerged, but

detecting recurrence, current

they're typically administered to

uses provide limited information

itients along with cytotoxic drugs.

as to whether a tumor will

is means a large percentage

respond to certain therapies. But

of patients with cancer are still

now, a new type of PET imaging

exposed to highly toxic levels of

may provide a more detailed

chemotherapy during treatment

assessment of tumors, thereby

and often experience debilitating

helping physicians to plan more

adverse effects as a result.

effective treatment strategies.

Positron emission tomography
(PET)—an imaging technique
developed at Mallinckrodt
Institute in the early 1970s to
measure bodily changes at the
molecular level—is one of the
methods used by oncologists to
eliminate some of the guesswork

Researchers at Mallinckrodt Institute recently began the first
human studies investigating how
imaging a certain cell receptor
can allow better understanding
about the size of a tumor and the
likelihood that it will respond to
certain treatments.

IMAGING THE BEHAVIOR
OF CANCER CELLS

!

Thus far, the use of PET scanning in oncology has largely focused
on a metabolic tracer known as
FDG, or flurodeoxyglucose. When
a patient is injected with this
radioactively labeled glucose, the
PET scanner can detect differences
in glucose use between tumors and
healthy surrounding tissue. This
measurement has proven useful in
diagnosing and staging tumors but
doesn't provide detailed information
for guiding treatment.
A new approach to using PET
in cancer imaging involves using
radiotracers that measure tumor
proliferation at the cellular level.

chemotherapy and to highdose radiotherapy, the risk
of using these treatments
is worth the high likelihood of benefit. But
tumors whose cells proliferate more slowly don't
respond any better to
aggressive radiation and
chemotherapy, and in
these cases the riskbenefit
ratio is too high to make
certain treatments worthwhile.
These patients would then be
treated with cell cycle nonspecific
agents and conventional radiotherapy, thus being spared the toxicities
of expensive treatments that are
unlikely to be effective.
In search of a method to image
cell proliferation, currently most researchers
are using radiolabeled
thymidine analogs
with PET. Tumors
undergoing rapid
growth and division
accumulate radiolabeled thymidine

In the Tissue Culture Room, Justin Rothfuss, senior
research technician, is using the inverted microscope;
Fanjie Chang is at the bio-safety cabinet.

"Thymidine is a good marker of
DNA synthesis, but this method
doesn't tell the whole story," says
Robert Mach, PhD, chief of
Mallinckrodt Institute's Radiological
Chemistry Laboratory. "Imaging
with radiolabeled thymidine
analogs underestimates the true
number of proliferating cells in a
tumor—an important distinction
in determining which treatment is
best for the patient."

"Looking at sigma-2 receptors to
image proliferation is an entirely new
approach, something different from
what everyone else is doing..."
Jinbin Xu, senior scientist, and (right) Robert Mach,
PhD, are in the Quality Assurance Lab for PET radiopharmaceuticals.

Having a measurement of cell
proliferation in patients with cancer
is useful for a number of reasons,
but particularly because it helps to
determine what type of treatment
is most appropriate for an individual
patient. For instance, because fast
growing tumors typically respond
well to cell cycle specific
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analogs, which can be detected by
PET imaging. When these agents
are injected into a patient, the PET
scanner measures the number of
cells that are in a state called "Sphase" (the synthesis phase of the
cell's life cycle). But only a small
percentage of cells in a tumor will
be in S-phase at any given time.
After S-phase, cells continue to
go through other phases of growth
and division, including a resting
period known as the Q-phase
(quiescent).

A NEW APPROACH
TO IMAGING TUMORS
Researchers are using a new
method to image cell proliferation
in tumors, using sigma-2 receptors
to directly visualize a tumor's
behavior. Sigma receptors, originally thought to be a subtype of
opiate receptors, are now recognized as a class of receptors
expressed in normal tissues,
including liver, kidneys, endocrine

15

IMAGING THE

the density of the
sigma-2 receptor in
quiescent tumor cells
is higher than that
reported in normal
cells, this imaging
strategy can also differentiate slow growing tumors from
healthy tissue.

DETERMINING
THERAPIES

Zhude Tu, PhD, research assistant professor of radiology,
with the fluoride chemistry system used in the production
of radiotracers.

glands, and, to a lesser extent, the
central nervous system. "Looking
at sigma-2 receptors to image
proliferation is an entirely new
approach, something different
from what everyone else is doing,"
says Mach, professor of radiology,
of cell biology and physiology, and
of biochemistry and molecular
biophysics.
As they relate to cancer treatment, sigma-2 receptors may be
most impressive for their ability
to reflect the entire life cycle of
cancer cells. This is because the
number of sigma-2 receptors in
proliferating tumor cells is 10
times higher than the number of
receptors in quiescent (resting)
tumor cells. This difference in density means that imaging the sigma-2
receptor status of tumor cells can
provide an accurate measure of the
tumor's overall proliferative status,
known as the P (proliferating):Q
(quiescent) ratio. Unlike the
method that uses thymidine
analogs, sigma-2 receptor imaging
clearly differentiates between proliferating tumor cells and quiescent
tumor cells. Furthermore, because
16

The implications
of a method for producing accurate P:Q
ratios are rewarding
for oncologists and
cancer patients alike.
Many of today's cancer treatments
are risky because of their high toxicities and price tags and, for that
reason, physicians would prefer to
know ahead of time how effective a
particular treatment is likely to be.
Sigma-2 receptor imaging may bring
them closer to that goal.
As solid tumors grow, even a
few millimeters, they outgrow their
blood supply. Areas of the tumor
are deprived of nutrients and exit
the cell cycle, a process that turns
them into quiescent, or nongrowing, tumors. Quiescent tumors cells
(the "Q" in the P:Q ratio) are more
resistant to treatment
than are proliferating
tumor cells. That
doesn't mean they're
not dangerous, but
rather that they are
unlikely to respond to
therapies that target
rapidly growing cells.

UNCOVERING LIGAND
FOR HUMAN TRIALS
Research on the sigma-2 receptor's role in reflecting cell proliferation goes back to 1995, when Mach
and Ken Wheeler, a cancer cell
biologist from Wake Forest University, began studying the expression
of the receptor in tumor cell cultures in mice. Known as "66 cells,"
the cells came from a breast tumor
line that grows in nutrient-deprived
conditions. These cells would grow
for four days, exit the cell growth
cycle, and go into a resting phase.
By observing this process,
researchers were able to detect
changes in tumor biology between
P and Q cells. They found that the
presence of sigma-2 receptors was
10-fold higher in proliferating
tumor cells than in quiescent tumor
cells, and the presence of sigma-2
in quiescent tumor cells was higher
than in normal cells. Their research
was published in Cancer Research
and the British Journal of Cancer.
Over the past seven years, the
Mach research group turned this
discovery into an imaging strategy
ready to be used in human study
volunteers. Since the concept was
entirely new, everything had to be
created from scratch—no small
feat in the world of molecular
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At top, sigma-2 receptors as
viable strategy for determining
proliferative status of solid
tumors. At bottom: MicroPET
images (left column); Coregistered images (middle column);
MicroCT images (right column).
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imaging. First they needed to find a
way to image the receptors with
PET scanning, which meant they
had to develop a ligand to bind to
the sigma-2 receptor. In most
research of this type, scientists can
choose from a few known ligands,

cell proliferation with
PET. In addition to providing more information
about the tumor itself, the
scientists found the new
technique yielded superior image quality as com-

"This may be useful for delivering treatments directly to the tumors, potentially
triggering the cancer to kill itself..."
but no such ligand was known for
the sigma-2 receptor. After a fiveyear effort, the research team
developed a sigma-2 selective molecule that could be labeled with a
radionuclide and tested in animal
models of cancer; in the following
years, they studied its use in imaging as well as its toxicity and
dosimetry (the right amount of the
agent to give and get a good picture
without causing adverse effects).
The animal studies concluded
that radioligands with a high affinity and a high selectivity for sigma2 receptors have the potential to
noninvasively image solid tumor

pared with other methods. The
technique has been licensed by Isotrace Technologies, Inc. and sublicensed to Bayer Schering Pharma
AG, which will sponsor the first
human clinical trials.
In a study led by Farrokh
Dehdasthi, MD, professor of radiology in Mallinckrodt Institute's Division of Nuclear Medicine,
researchers are now trying to
reproduce in humans the success
found in the animal studies. The
initial trials will focus on breast
cancer since it's the type of cell
originally validated in animal models, as well as patients with head
and neck
cancer and
lymphoma.
Future studies will likely
include
patients with
lung cancer
and brain
tumors.

Greg Gaehle, cyclotron manager, and (right) Robert
Dennett, cyclotron supervisor, with the 10-ton,
self-shielded Siemens RDS Eclipse cyclotron, which
was installed in February 2002. Also shown are the
target support unit and power supplies.

Long-range plans include studying
this type of imaging for the delivery
of toxic agents. "Sigma-two receptors on the membrane, mitochondria, and endoplasmic reticulum
are linked to the cell death pathway," explains Mach. "This may be
useful for delivering treatments
directly to the tumors, potentially
triggering the cancer to kill itself."
As scientists like Mach expand
our ever-growing understanding of
cancer, we look forward to safer
and more effective treatments.
Though it's likely to be some time
before sigma-2 imaging makes it to
the marketplace, the dedication
that brought us here is what perpetuates cancer patients' hope for
the future. Una

Cell culture study showing high density of sigma-2 receptors in tumor cells
(green). Tracker experiments show that sigma-2 receptors are not in the nucleus
(DAPI/blue) but are in high localizations in the mitochondria and endoplasmic
reticulum (both shown in red). The merger of images red and green (resulting in
yellow for colocalization) suggest that sigma-2 receptors ligands may be useful in
delivering anticancer agents to key intracellular organelles that regulate cell death.
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IMAGING IS KEY TO ACCURATE DIAGNOSIS
by Mary Jo Blackwood, RN, MPH

Nothing is worse for a parent than to
have a child in pain and not know what is
causing the pain or what to do about it.
Our greatest fears are about cancer, a massive infection, or a progressive
chronic disease. Having a doctor rule out those conditions is only one
step in determining what is causing your child's illness.
Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory
disease that mostly affects children and young adults, is slightly more
common in girls than in boys (a ratio of 5:1), and typically develops in
children between the ages of four and 14 (with 10 being most common).
While CRMO is noninfectious and noncancerous, the disease is often
misdiagnosed because of its rarity—and that misdiagnosis can lead to
multiple bone biopsies and long-term antibiotic therapy.

WHAT IS CRMO?

Geetika
Khanna, MBBS,
MS, a pediatric
radiologist,
recently
came to
Mallinckrodt
Institute
from the
University
of Iowa,
where she
studied CRMO
extensively. Her
youngest patient
was a six-month-old

IFOCAL
infant. "Typically around the age
of ten, these children present with
bone pain that seems to move
around and sometimes with a
low-grade fever," she says. "With
conventional X ray, we may detect

a bone lesion and then biopsy it.
But there is no infection, only
inflammation that occurs in the
bone and typically in the long bones
close to the growth plates, which
can affect a child's growth if the
inflammation is not brought under
control. We're not sure why patients
develop this condition, but it seems

c

such as psoriasis and inflammatory
bowel disease. Patients typically
have debilitating, multifocal bone
pain caused by the inflammation.
Since the medical community
became aware of the disease more
than three decades ago, several
hundred cases of CRMO have been
reported. Because there is no

'TYPICALLY AROUND THE AGE OF TEN, THESE
CHILDREN PRESENT WITH BONE PAIN THAT SEEMS
TO MOVE AROUND AND SOMETIMES WITH A
LOW-GRADE FEVER..."

OSTEOMYELITIS
to have some genetic component."
CRMO is characterized by
nonbacterial osteomyelitis, or
bone inflammation with a remitting,
relapsing course, and an association
with other inflammatory disorders

specific diagnostic test for CRMO,
it remains a diagnosis of exclusion,
making it likely that the number of
cases is much higher than reported.
Why people develop CRMO
remains somewhat elusive. "The
association of CRMO with dermatologic disorders such as psoriasis
and inflammatory bowel disease,
along with its response to steroids,
indicates a possible autoimmune
etiology. More recently, a genetic
etiology has been suggested, based
on observation of the disease in
siblings and monozygotic twins,"
says Khanna. "Another fact pointing to a genetic cause is Majeed
syndrome, an autosomal recessive
disorder of CRMO with congenital
dyserythropoietic anemia, which is
associated with mutations in the
LPIN-two gene."
Geetika Khanna, MD, in the entrance to the Jack
Buck Imaging Center at St. Louis Children's Hospital
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A CASE STUDY
MAKING THE DIAGNOSIS

An eight-year-old girl pre-

The disease has characteristic
findings— including lesions in the
metaphyses of long bones (such as
in the leg) and the medial clavicle
(or collarbone)—and is most often
diagnosed by a radiologist due to
its typical imaging findings. The
metaphyses are the primary site of

sented with acute onset pain
in her left hip. One month
alter presentation, plain radiographs showed a lytic lesion
at the greater trochanter (part
of the thigh bone); biopsy

OTHER COMMON SITES

revealed nonspecific inflam-

FOR THE DISEASE

mation. Two years later, the

INCLUDE THE VERTE-

patient developed severe

BRAL BODIES, PELVIS,

pain in the chest wall. A

RIBS, AND MANDIBLE.

chest X ray showed an

CRMO IS OFTEN BILAT-

expanded sclerotic right-

ERAL AND MULTIFOCAL

third rib with permeative

AT PRESENTATION.

lytic areas. Bone biopsy
bone growth in children. Because
of their rich blood supply, the
metaphyses of long bones are prone
to hematogenous spread of infection
in children. Hence, a bone biopsy is
often required to exclude the possibility of infectious osteomyelitis or
a tumor such as histiocytosis.
Other common sites for the
disease include the vertebral
bodies, pelvis, ribs, and mandible.
CRMO is often bilateral and multifocal at presentation. However,
because many of the lesions are
asymptomatic at any given time,
the patient may undergo conven-

showed nonspecific inflammation. Magnetic resonance
imaging of the chest confirmed the inflammatory
lesion of the rib and revealed
additional vertebral body
lesions. A diagnosis of
CRMO was suggested, and
the patient was started on
anti-inflammatory therapy.
She has had no major disease exacerbations for two
years since starting
methotrexate. She continues
to have intermittent shortlived episodes ot mild bone

Classical findings of CRMO as seen in the case study:

pain, but they do not interfere

sclerosis and expansion of the medial clavicle, unilat-

with her activities.

contiguous vertebral bodies with sparing of the inter-

eral sacroilitis, vertebra piano and involvement of
vening disc space.
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RECURRENT
tional radiographs for the painful
area, which, without information
about other bone involvement, may
lead to an erroneous diagnosis. As
the imaging appearance of CRMO
can mimic other entities like infection and tumors, awareness of
other asymptomatic sites of disease
can aid the diagnosis of CRMO.
While at the University of Iowa,
one of Khanna's patients was a girl
who had undergone multiple surgeries on her jaw and was on longterm antifungal treatment. When
Khanna performed more extensive
imaging, she found lesions in the
girl's clavicle, a classic marker for
CRMO, and unique among bone
conditions in its involvement of
the clavicle.
According to Khanna, magnetic
resonance imaging (MRI) can
demonstrate associated periostitis,
soft tissue inflammation, and
synovitis—findings initially
believed to be more typical for
infectious osteomyelitis rather than
CRMO. MRI is more sensitive than
conventional imaging in detecting
transphyseal spread of disease,
which can result in growth deformities and, thus, has prognostic
significance.

TREATMENT FOR CRMO

Nonsteroidal anti-inflammatory
drugs (NSAIDs), such as aspirin
and ibuprofen, are the mainstays of
therapy, and most patients do quite
well on these. For patients who do
not respond to NSAIDs, treatment
may include steroids, methotrexate,

were referred to the University
of Iowa's Department of Pediatric
Rheumatology: 10 boys and 15 girls
with an average onset of symptoms
at 8.3 years. Khanna and Ferguson
found these sites of disease at
initial presentation to be the
most common: lower extremities

MRI IS MORE SENSITIVE THAN CONVENTIONAL IMAGING
IN DETECTING TRANSPHYSEAL SPREAD OF DISEASE,
WHICH CAN RESULT IN GROWTH DEFORMITIES AND,
THUS, HAS PROGNOSTIC SIGNIFICANCE.
and other immunosuppression
drugs, particularly when CRMO is
associated with a rash, arthritis,
and a high probability of growth
deformities.
FURTHERING EFFECTIVE
DIAGNOSIS OF CRMO

While at the University of Iowa,
Khanna worked closely with her
rheumatology colleague Polly Ferguson, MD, observing patients and
reviewing imaging studies sent
from all parts of the country and
even some from outside the United
States. They compiled case after
case of diagnosed CRMO, with all
of its variations in individual children. Twenty-five cases of CRMO

(39.7 percent), spine (25.9 percent),
and pelvis (20.7 percent). During
the three-year average follow-up
care, a total of 121 bone lesions
were seen in this patient population
of 25. Metaphyseal lesions were the
most common, accounting for 49
percent of all bone lesions.
Their initial research findings
were presented in 2008; subsequent
findings will be published in the
July 2009 issue of RadioGraphics.
Radiological evidence is still being
collected, both at the University of
Iowa and at Mallinckrodt Institute,
to amass information needed for
future clinical trials on the identification and treatment of CRMO.
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MULTIF
FUTURE DIRECTIONS FOR CRMO
In September 2008, a National
Institutes of Health conference/
CRMO workshop was held in
Bethesda, Maryland, bringing
together international clinical and

and scoring of CRMO bone lesions
to assess response to treatment. A
Washington University colleague,
Deborah Novack, MD, assistant
professor of pathology and immunology, spoke on the immunological

...THE GOAL OF CREATING A CONSENSUS FOR THE
DEVELOPMENT OF STUDY INCLUSION CRITERIA,
OUTCOME MEASURES TO IDENTIFY RESPONSE TO
TREATMENT, AND BIOMARKERS OF DISEASE ACTIATTY.
research experts to define the criteria for diagnosis of this condition
and to identify the clinical markers
that can be used for future clinical
trials. At the conference, Khanna's
presentation focused on using multimodality imaging for diagnosis

study entry criteria, rheumatology
and rehabilitation endpoints, and
biomarkers for inflammation, bone,
and GI tract—with the goal of
creating a consensus for the
development of study inclusion
criteria, outcome measures to
identify response to treatment,
and biomarkers of disease activity.
The proceedings from this workshop
will be used to develop a multicenter trial for follow-up care of
children with CRMO. EM

evaluation of CRMO bone lesions.
Following the presentations on
state-of-the-art technology in all
aspects of this disease, conference
attendees participated in concurrent
workshops focusing on scoring of
imaging findings, skin scoring,

CLINICAL PRESENTATION OF CRMO
• History of pain, tenderness, swelling, and limited
range of joint motion
'Duration of symptoms: from a few days to
several years
»Inconclusive laboratory findings, such as a mildly
elevated ESR (erythrocyte sedimentation rate or
how fast red blood cells fall through a column of
blood) and CRP (C-reactive protein found in
blood in response to inflajja^""^anri ■•■mal
WBC (white blood c-

>Bone scan or magnetic resonance imaging reveai
bilateral, multifocal areas of bone inflammation,
even if asymptomatic
>Most common bones affected: the long bones,
medial clavicle. Other common sites: vertebral
bodies, ribs, and mandible
> Possible other symptoms: skin lesions
(eg, psoriasis) and inflammatory bowel conditions

A
A-ray inaicdiiori 01

bones near physe
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Assessing breast cancer treatment
by Amy Thomas, MD, FAAP

As the most common cancer in females,
breast cancer ranks high as a potential threat to a woman's vitality. But as physicians and
scientists understand more about the nature of breast cancer, new treatments are being
discovered and women are living longer even when they have advanced disease. Recently,
research conducted at Mallinckrodt Institute of Radiology has made a marked contribution
to the race for a cure—a novel way of assessing the best treatment for breast cancer in
patients who have exhausted most available therapies. This new approach to a common
imaging technique allows doctors to predict a tumor's response after only a few days of
treatment. The insight gained not only helps to guide patients with limited options to the
next best treatment choice, but it also unlocks incredible potential for the investigation of
new breast cancer treatments that, hopefully, will give women even more time for life.

"IWOF CANC

he Discovery targets
Ja key question in treating breast
cancer: Will the tumor respond to
hormone manipulation? The presence
of functioning hormone receptors on
breast cancer tumor cells, including
those that react with estrogen or
progesterone, suggests the cancer will J
respond to a number of hormone
therapies and generally will be mum
easier to treat as compared with tumors1
that lack hormone receptors. Though
it is simple to detect the presence of
hormone receptors on a newly diagnosed cancer, doctors do not always
know whether or not the receptors are
functioning and if the tumors will
respond to hormone therapy. This is
especially problematic in patients with
metastatic disease because some
tumors lose their receptors over time,
while others continue to have hormone
receptors that are longer functioning.
Farrokh Dehdasthi, MD, professor of
radiology in Mallmckrodt Institute's
Division of Nuclear Medicine, is investigating the ability of an imaging test to
determine the functional status of
hormone receptors—a simple set of

Predicting patients' response
to hormone therapy
Dehdashti currently is studying
a breast cancer phenomenon called
"flare"—breast cancer's paradoxical
response to treatment that will
eventually be effective. One in 20
women who receive hormone
therapy for breast cancer will
experience an initial phase of
tumor growth, and this is the flare
response. It typically indicates that
after the initial growth phase, the
tumor will respond well to hormone

often impractical for patients with
metastatic disease whose tumors
are hard to reach. This leaves the
remaining patients and their doctors
with a difficult decision: try additional hormone agents or move on
to other lines of treatment.
Though clinical flare is helpful
in predicting response to treatment,
only a small portion of women with
breast cancer will experience physical signs of flare, such as swelling
or pain at the site of the tumor or
tumor metastasis. A larger portion

One in 20 women who receive hormone
therapy for breast cancer will experience
an initial phase of tumor growth, and
this is the flare response.
therapy and subside with further
treatment. More simply put: If a
tumor reacts to the administration
of hormones either by growing
or shrinking, it must have functioning receptors.
Once doctors know that the
hormone receptors are functioning,
they can offer the patient a number
of hormonally derived cancer
treatments that are less toxic and
less expensive than traditional
chemotherapy. And those women
with unresponsive tumors can
proceed with therapies that have a
better chance of helping their
particular tumor. Biopsy can
differentiate whether a tumor has
receptors, but many tumors with
receptors present still do not
respond because the receptors are
not functioning. And biopsy is

of women will have a response
termed "subclinical flare" in which
the tumor does have a short period
of growth related to treatment, but
the patient has no physical indication this is happening. Since it is
known that women with any flare
reaction tend to respond well to
hormone therapy, doctors have
looked for a way to detect which
women have subclinical flare
and should also be treated with
continued hormonal therapy.
In her past and current research,
Dehdashti is finding new ways to
determine the functional status of
estrogen receptors, including the
ability to use positron emission
tomography (PET) to detect the
presence of subclinical flare. The
idea of imaging flare originated

pictures to predict how an individual's
tumor will respond to treatment.
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from the known effects of tamoxifen, an agent often used to treat
hormone-responsive breast cancer.
Tamoxifen is a hormone-blocking
agent that has pro-estrogen effects
for approximately the first seven
days it is given to a patient. The
initial pro-estrogen phase is then
followed by an anti-estrogen effect
that is often used to treat women
with hormone-responsive breast
cancer. "If we can assess the
effect of tamoxifen on the estrogen
receptor, we can determine the
receptor's functional status,"
says Dehdasthi.
Detecting subclinical flare
Dehdasthi is able to visualize
a tumor's response to a hormone
challenge by using PET, which
detects a growing cancer's hearty
appetite for glucose. A patient is
injected with glucose combined
with a radioactive tracer (fluorine18 fluorodeoxyglucose, or FDG),
and the PET scanner is able to
detect and localize the tagged
glucose within the body. PET imaging takes advantage of the fact that
rapidly growing cells, like cancer
cells, use more glucose than normal
cells, and typically a cancer will
have an increase in glucose
utilization during a growth spurt.

"If we can assess
the effect of
tamoxifen on the
estrogen receptor,
we can determine
the receptor's
functional status"
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Dehdashti and Siegel are in the PET-CT scanning area in MIR's Center for Clinical Imaging Research, the nation's
only research-dedicated, comprehensive imaging facility in the center of a major hospital.

By performing a baseline PET scan
followed by a repeat PET scan
about one week after a patient
begins taking tamoxifen, doctors
can predict response by comparing
the difference in tumor activity on
each scan. If the demand for glucose increases just after tamoxifen
is introduced, then it is clear that
the estrogen receptors are responding and functional. In other words,
the patient is experiencing a flare
response, known by doctors as
"metabolic flare." In more recent
studies, Dehdashti has shown that
the flare can be detected after just
one day of tumor stimulation with
an estrogen drug.

Once the detection of flare
determines a patient's tumor has
functioning hormone receptors,
that patient can then begin or
resume hormone therapy knowing
there is a high likelihood the tumor
will respond to treatment. If the
receptors are shown to be unresponsive by imaging, the doctor
knows the tumor is unlikely to
respond to a course of hormone
therapy and can move on to more
aggressive chemotherapies for
treatment. The ability to treat a
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FDG—PET/CT
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SUV = 6.4
24 HOURS AFTER ESTRADIOL

SUV = 8.3
In bottom right image, metabolic flare reaction is
shown as a 12% or greater increase in standardized
uptake value (SUV), indicating a response to
endocrine therapy.

cancer with hormone therapy is
advantageous for many reasons:
• Hormone therapy is generally less
toxic than chemotherapy.
• The adverse effects are generally
better tolerated than those
related to chemotherapy.
• The cost of using hormones to
treat cancer is significantly less
than with other treatments.
Impact on quality of life
Barry Siegel, MD, professor of
radiology and of medicine, and
chief of Mallinckrodt Institute's
Division of Nuclear Medicine, has
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"..♦We must show not only that this
technique can properly predict response,
hut that it also improves the quality
of a patient*s life"
collaborated with Dehdasthi in
looking at PET's ability to detect
flare. "The results are encouraging,"
says Siegel. "Now we must look at
survival data and compare outcomes, adverse effects, and cost."
The next step for researchers
is to compare whether the use
of PET to predict flare makes a
significant difference in the lives
of those with breast cancer. "We
know it's good, but is it good
enough? We must show not only

that this technique can properly
predict response, but that it also
improves the quality of a patient's
life," says Siegel.
Matthew Ellis, MB, BChir, PhD,
professor of medicine, is enthusiastic about Dehdashti's work. He
is head of the Medical Oncology
section at Washington University
School of Medicine (WUSM) and
director of the Breast Cancer
Program at the Alvin J. Siteman
Cancer Center at WUSM and
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Barnes-Jewish Hospital. Ellis relies
on knowing the functional status
of estrogen receptors to provide
the right treatment for his patients.
"For patients with estrogen receptor [ERJ-positive breast cancer, the
manipulation of estrogen levels is
critical to treatment. But it doesn't
work in everyone, even in the presence of ER-positive tumors. The
goal is to predict who will do well."

\
|
|

Improving clinical research
In addition to its potential for
clinical use, the ability of PET to
predict the functional status of
estrogen receptors in breast
tumors is also a great boost to
research. Therapeutic agents
designed for use on hormonally
responsive tumors can be tested on
those likely to respond. "This helps
us to study the effectiveness of

"This helps us to study the effectiveness
of new therapies without fighting the
battle against tumors that would he
unresponsive anyway"
Ellis recently collaborated with
Dehdashti and Siegel in studying an
estrogen regimen for patients with
metastatic breast cancer who have
become resistant to certain treatments. The investigators suspect
that daily estrogen therapy could
wipe the resistance slate clean in
some patients who have exhausted
other options, and that PET could
be a useful
predictor of
likely success
in this group
of women.
Their findings
have been
submitted for
publication.
Ellis is a member
of the Breast Cancer
Committee of the
American College
of Surgeons
Oncology Group.

FOCAL SPOT, SPRING 2009

new therapies without fighting the
battle against tumors that would be
unresponsive anyway," says Ellis.
By eliminating the subset of tumors
that wouldn't respond to any hormone manipulation, researchers
can get a better idea of a new agent's
efficacy in the target group of
patients with functioning hormone
receptors on their tumors.
And it is these newer and
more effective agents thought to
be, in part, responsible for the
improvement seen in breast cancer
patients' survival. Even women
with advanced disease are living
longer with the treatments available now. As scientists investigate
treatments for those who have
exhausted their options, new
research is bringing hope to those
who had none. And the research
at Mallinckrodt Institute is already
changing the clinical practice
across the United States. ED3
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Risk factors for
breast cancer
gender—100 times more common
among women than men
aging—risk doubles in women
aged 55 years or older

family history—20% to 30% of
women with the disease have a
family member with the disease
race and ethnicity—Caucasians
are slightly more likely to develop
the disease than are other races
or ethnicities
dense breast tissue—more
glandular tissue and less fatty tissue
increase risk

lifestyle-related factors—
including use of alcohol, being
overweight or obese, lack of
physical activity

Information excerpted from the
American Cancer Society Web site
at www.cancer.org.

NEW FACULTY
Larry Bretthorst, PhD,
research associate professor
of radiology, Division of
Radiological Sciences.
Monica Shokeen PhD,
instructor in radiology, Division of Radiological Sciences.
Thaddeus Wadas, PhD,
instructor in radiology, Division of Radiological Sciences.

PROMOTIONS
Barry Edwards, PhD,
research instructor in
radiology, was promoted
to assistant professor of
radiology, Division of
Radiological Sciences.
David Gierada, MD, associate professor of radiology,
was promoted to professor
of radiology, Division of
Diagnostic Radiology.
Michael Penney, MD,
instructor in radiology, was
promoted to assistant professor of radiology, Division
of Diagnostic Radiology.
Suresh Vedantham, MD,
associate professor of radiology, was promoted to professor of radiology, Division of
Diagnostic Radiology.
Daniel Wessell, MD, PhD,
instructor in radiology, was
promoted to assistant professor of radiology, Division
of Diagnostic Radiology.
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JOINT
APPOINTMENTS
Jin-Moo Lee, MD, PhD,
associate professor of neurology, was appointed associate
professor of radiology, Division of Radiological Sciences.
Suresh Vedantham, MD,
professor of radiology, was
appointed professor of
surgery, Department of
Surgery.
Younan Xia, PhD, professor
of biomedical engineering,
was appointed professor of
radiology, Division of Radiological Sciences.

GRANTS
Carolyn Anderson, PhD,
professor of radiology, of
molecular biology and pharmacology, of chemistry, and
of biochemistry, as principal
investigator, received a
$292,410 four-year renewal
grant from the National Institutes of Health for research
on "Labeling of octreotide
with positron emitters."

Thomas Conturo, MD,
PhD, associate professor of
radiology, of physics, and of
biomedical engineering, as
principal investigator,
received a $456,000 grant
from the U.S. Department of
Defense to study "Breast
cancer diagnosis and therapy
monitoring." Collaborators
for the three-year grant are
Erbil Akbudak, PhD,
research assistant professor
of radiology, and Hsui-San
Lin, MD, PhD, Washington
University Department of
Radiation Oncology. Conturo, as subcontract
principal investigator, and
Rob Paul, PhD, University
of Missouri, St. Louis, as
overall principal investigator, received a $3.1 million
grant from the National Institutes of Health for research
on "Neuromarkers of agerelated cognitive decline."
Collaborators for the five-year
grant are Akbudak, Eren
Gultepe, and Amanda
McMichael, MS.

Yuan-Chuan Tai, PhD,
associate professor of radiology, as principal investigator,
received a $2.2 million grant
from the National Cancer
Institute, National Institutes of
Health, for "A sub-millimeter
resolution add-on for animal
PET scanners." Stefan
Siegel, Siemens Molecular
Imaging, KnoxvUle, Tennessee,
is coprincipal investigator
for the five-year grant;
Joseph O'Sullivan, PhD,
Washington University
Department of Electrical
and Systems Engineering,
is coinvestigator.

Steven Don, MD, associate
professor of radiology,
received the Society for
Pediatric Radiology's 2009
John Dorst-Felix Fleischner
Seed Grant of $10,000 for
research on "Mathematical
modeling of pediatric
pulmonary nodules."

Nassir Siddiqi, MD, assistant professor of radiology,
was elected chairman of the
Continuing Medical Education Committee of the King
Edward Medical College
Alumni Association. He was
appointed to membership of
the Society of Interventionsj
Radiology's Standards of
Practice Committee, the
Publications Advisory Conv
mittee, and the Oncology
Task Force. He also was
appointed to the Washingto
University in St. Louis Institutional Review Board.

Fred Prior, PhD, research
associate professor of radiology, as principal investigator, received a one-year,
$1.9 million grant from the
National Institutes of Health
to fund the project "High
performance biomedical
imaging computer resources."

APPOINTMENTS/
ELECTIONS
Bennett Greenspan, MD,
instructor in radiology, was
named editor of the Nuclear
Medicine Science Syllabus,
5th edition, published by the
American Board of Science
in Nuclear Medicine.
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Samuel Achilefu, PhD,
professor of radiology and of
biochemistry and molecular
biophysics, was named session chair of "New activation
strategies in molecular imaging" at the 100th Annual
Meeting of the American
Association for Cancer
Research, Denver, Colorado,
April 18-22.
Naganathan Mani, MD,
instructor in radiology,
received the eighth highest
score among all physicians
who participated in the
Korean Society of Thoracic
Radiology's 2008 weekly
chest case quiz.
Fred Prior, PhD, research
associate professor of radiology, received his fifth year
of funding as a Subject
Matter Expert for the Cancer
Bioinformatics Grid (caBIG)
program.

LECTURES
Samuel Achilefu, PhD,
professor of radiology and of
biochemistry and molecular
biophysics, as Ground
Rounds Speaker, presented
"Optical imaging: a unique
and complementary imaging
modality" at Thomas Jefferson University, Philadelphia,
Pennsylvania, February 24.
He spoke on "Optical techniques of bioluminescence
& fluorescence" at the International Symposium on
Molecular Imaging and Therapy: Road Map to Modern
Medicine, Kuwait University,
Kuwait City, March 9-12. He
presented "Flip-flopping
contrast mechanisms in
molecular optical imaging
of tumor cells and tissues"
as part of the Faculty of
Graduate Studies Lecture
Series, Loma Linda University, California, April 14.

Carolyn Anderson, PhD,
professor of radiology, of
molecular biology and pharmacology, of chemistry, and
of biochemistry, spoke on
"Copper-64-labeled biomolecules for molecular imaging
of cancer metastasis" at the
Duke University Workshop:
Clinical Directions for Molecular Imaging, Durham,
North Carolina, March 12,
and at Johns Hopkins University, Baltimore Maryland,
March 25. She presented
"Nuclear and radiochemistry
at Washington University in
St. Louis" at the MARC VIII
Conference, Kona, Hawaii,
April 15-10.
Delphine Chen, MD, assistant professor of radiology,
spoke on "Imaging intracellular markers of apoptosis"
at the Transatlantic Airway
Conference, sponsored by
Boehringer-Ingelheim,
Lucerne, Switzerland, January 22 and 23. She presented

"FDG-PET imaging as a biomarker for neutrophilic lung
inflammation" as part of the
Nuclear Medicine Research
Seminar Series, Massachusetts
General Hospital, Boston,
April 3.
Nirvikar Dahiya, MD,
assistant professor of radiology, presented "Acquiring a
3-dimensional ultrasound
image: basic principles" and
moderated "Nonobstetric
applications of a 3-dimensional ultrasound: improving
productivity and workflow"
at the 2009 Annual Convention of the American Institute
of Ultrasound in Medicine,
New York City, April 2-5. He
spoke on "Ultrasound evaluation of liver transplant and
ultrasound evaluation of
thyroid lesions" at USCON
XVIII, the Annual Conference
of the Indian Federation of
Ultrasound in Medicine and
Biology, Goa, India, April 30May3.

Biello Lecture
Chaitanya Divgi, MD, professor of
radiology, University of Pennsylvania;
chief, Nuclear Medicine and Clinical
Molecular Imaging, Hospital of the
University of Pennsylvania, Philadelphia,
was guest speaker for the Twenty-third
Annual Daniel R. Biello Memorial Lecture
on March 11. He presented "Back to the
future in nuclear medicine: developments
and integration."

Divgi (left) with Barry Siegel, MD, thief, Division of Nuclear Medicine.
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LECTURES
Continued from page 29
Colin Derdeyn, MD, professor of radiology and of
neurology and neurological
surgery, presented
"Overview of cerebral hemodynamics" at the 9th Annual
International Meeting on
Cerebral Revascularization,
St. Louis, Missouri, January
8; at Radiology Grand
Rounds, Department of Radiology, University of Virginia,
Charlottesville, March 9; and
at the Alleghany Regional
Hospital Neuroscience
Grand Rounds, Pittsburgh,
Pennsylvania, March 25. He
spoke on "Intracranial atherosclerotic disease and the
SAMMPRIS Trial" at the
Cedars-Sinai Neurovascular
Symposium, Los Angeles,
California, January 10.
Derdeyn spoke on "Natural
history of intracranial atherosclerotic disease" at the
annual meeting of the Joint

Section on Cerebrovascular
Disease, San Diego, California, February 17. He presented
"Stenting versus Aggressive
Medical Management for the
Prevention of Ischemic Stroke
(SAMMPRIS) Trial update"
at the 34th International
Stroke Conference,. San Diego,
California, February 20.
Louis Gilula, MD,
professor of radiology, of
orthopaedic surgery, and of
plastic and reconstructive
surgery, spoke on "A twoyear follow-up for intergroup
study of Cortoss™ for vertebroplasty" at the 2009
Annual Symposium of the
American Society of Spine
Radiology, Lake Buena Vista,
Florida, February 19-22. He
presented "Imaging interpretation of hand and wrist,
emphasis on trauma" at the
41st International Diagnostic
Course, Davos, Switzerland,
March 29-April 30.

In January 2009, Louis Gilula, MD, professor of radiology, of orthopaedic surgery, and of plastic and reconstructive surgery, was invited, as a radiology expert, by
the Singapore Ministry of Health to present a series of
lectures to the departments of radiology at five medical
facilities: Changi General Hospital, Singapore General
Hospital, Alexandra Hospital, National University Hospital, and Tan Tock Seng Hospital. He gave the following
presentations: "Board review tutorial to residents,"
"Entities of the wrist which are not commonly known,"
"Analysis of complex carpal trauma," "Vertebroplasty:
basic principles and technical aspects," "Radiographic
findings in hand and wrist surgery," "Approach and
overview to trauma," "Cervical spine nerve blocks,"
"Nerve root blocks and central epidural blocks for neck
and low back pain," "Cervical spine trauma," "Facet
blocks and radiofrequency ablation of facet nerves,"
"Ligamentous instabilities of the wrist," and "Vertebroplasty: current status and problem solving."

Bennett Greenspan, MD,
instructor in radiology,
presented "Diagnosis and
therapy of hyperthyroidism"
at Grand Rounds at the Habif
Health and Wellness Center,
Washington University in St.
Louis, January 14.
Perry Grigsby, MD, professor of radiation oncology, of
radiology, and of gynecologic
oncology, spoke on "The use
of PET/CT for simulation,
treatment planning, and
IMRT guided therapy for cervical cancer" and "The use of
PET/CT in cervical cancer
to assess response during
therapy, after completion of
therapy, and for long-term
follow-up" at the 2009 First
Multidisciplinary PET/CT
Oncology Symposium,
San Juan, Puerto Rico,
January 31.
Jay Heiken, MD, professor
of radiology, spoke on
"Distinguishing benign from
malignant liver tumors," "CT
and MR in the detection and
staging of pancreatic cancer," "Evaluation of the liver
after transarterial chemoembolization," and "Contrast
safety in the cancer patient"
at the first RSSA/ICIS Cancer
Imaging Course, sponsored
by the Radiological Society
of South Africa and the International Cancer Imaging
Society, Cape Town, South
Africa, February 6-8. He presented "Abdominal aortic
aneurysm rupture," "CIN and
contrast use in subjects with
renal dysfunction," "MDCT
of bowel obstruction," "CT
colonography techniques,"
and "CT colonography clinical trial results" at Masters in
Body Imaging, 2009 Annual
Course of the Society of
Computed Body Tomography
and Magnetic Resonance,
Miami Beach, Florida,

March 1-6. As a visiting
professor, he spoke on
"Acute mesenteric ischemia:
MDCT evaluation" and "Cystic pancreatic neoplasms:
diagnosis and clinical management" at Yale University,
New Haven, Connecticut,
April 2.
Charles Hildebolt, DDS,
PhD, professor of radiology
and of anthropology, presented "Virtual hobbits and
health in Homo floresiensis"
at Hobbits in the Haystack:
Homo floresiensis and
Human Evolution, the
Seventh Human Evolution
Workshop sponsored by the
Turkana Basin Institute, at
Stony Brook State University
of New York, April 21.
Rebecca Hulett-Bowling,
MD, assistant professor of
radiology, spoke on "Imaging
of pediatric tuberculosis and
other infections" at the
Queen Elizabeth Hospital,
Maseru, Kingdom of
Lesotho, Africa, February 16.
Seung Kwon Kim, MD,
assistant professor of radiol
ogy, presented "Fluoroscopi''
placement of self-expanding
metallic stent for the treatment of obstructing left-side I
colorectal cancer" at the
European Congress of
Radiology, Vienna, Austria,
March 6-10.
Robert McKinstry, MD,
PhD, associate professor o
radiology and of pediatrics,
as Radiology Grand Round;
speaker, presented "Imagin
of brain injury in newborns
and "Neuroradiology cases
from the Mallinckrodt
Institute of Radiology" at
Brigham and Women's Hos
pital, Boston, March 31, am
at Massachusetts General
Hospital, Boston, April 1.
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Michelle Miller-Thomas,
MD, instructor in radiology,
spoke on "Temporal bone
| imaging" at the University
of Texas Health Sciences
Center, Houston, March 16.
Nassir Siddiqi, MD, assistant professor of radiology,
; spoke on "Chemoembolization for liver tumors" at the
Nurses Continuing Education Lecture, sponsored by
Barnes-Jewish Hospital and
the Center for Advanced
Medicine, St. Louis, Missouri,
March 6. He presented
"Venous thromboembolism
and IVC filters" at the King
Edward Medical College
Alumni Annual Meeting,
St. Louis, Missouri, March 28.
Barry Siegel, MD, professor
of radiology and of medicine,
presented "Sponsorship and
economics of imaging trials
and research billing compliance" and "Practicalities of
running a clinical trial" at the
Radiological Society of
North America Clinical Trials Methodology Workshop,
Phoenix, Arizona, January

10-16. He spoke on "PET
reimbursement and the
National Oncologic PET Registry" and "PET and PET/CT
in oncology: monitoring and
predicting response to
therapy" at the 2009 First
Multidisciplinary PET/CT
Oncology Symposium, San
Juan, Puerto Rico, January
31. He spoke on "Update on
reimbursement of PET and
the NOPR" and "Cervical
cancer" at Advances in
Whole Body Fusion Imaging:
PET/CT and SPECT/CT,
Johns Hopkins University,
Baltimore, Maryland, March
13 and 14. Siegel presented
the Fifth Annual Maxfield
Lecture—"PET reimbursement and NOPR"—and "PET
& PET/CT: predicting and
monitoring response to
therapy" at the 54th Annual

Meeting of the Southwestern
Chapter, Society of Nuclear
Medicine, Houston, Texas,
March 20-22. As invited
speaker, he presented "PET
as a biomarker in early cancer treatment trials" at the
City of Hope Comprehensive
Cancer Center's 2nd Developmental Cancer Therapeutics/
Phase 1 Retreat, Pasadena,
California, April 4.
Michael Welch, PhD,
professor of radiology, of
chemistry, and of molecular
biology and pharmacology,
as invited speaker, presented
"Functional imaging micro
PET" at the City of Hope
Comprehensive Cancer
Center's 2nd Developmental
Cancer Therapeutics/Phase 1
Retreat, Pasadena, California,
April 4.

Senturia
Lecture
On April 28, Debra
Gervais, MD, associate
professor of radiology,
Harvard Medical
School; director, Interventional Abdominal
Imaging, Massachusetts
General Hospital, Boston, presented the Fifteenth Annual Hyman R. Senturia Lecture. She spoke on "Percutaneous ablation of hepatic malignancies: current status
and future directions."
Michael Darcy, MD, thief, Intervention^ Radiology, presented Gervais with a commemorative plaque.

SYMPOSIA
In this section ofFYI, only
those faculty and staff who
have Department of Radiology appointments are listed.

SOCIETY OF INTERVENTIONS RADIOLOGY

34th Annual
Scientific Meeting
San Diego, California
March 7-12, 2009

FEATURED SYMPOSIUM
Michael Darcy, MD, "TIPS
too long"; "SIR Foundation
and SIR: the big picture."

VEIN CASE-BASED REVIEW
Suresh Vedantham, MD,
"Cases 4-6."

CATEGORICAL COURSES
Michael Darcy, MD, "Portomesenteric venous thrombolysis—Ho w-I-do-it."
Suresh Vedantham, MD,
"The ATTRACT trial and the
big picture on DVT."

SCIENTIFIC SESSION
Seung Kwon Kim, MD,
"Clinical efficacy of peritoneal ports for management
of intractable ascites using
ports designed for venous
access."

SOCIETY FOR PEDIATRIC
RADIOLOGY
52nd Annual Meeting and
Postgraduate Course
Carlsbad, California
April 21-25, 2009
Tejaswini Deshmukh, MD;
Prakash Masand, MD;
Robert McKinstry, MD,
PhD, "MR imaging features
of the malformations of
cortical development in
children."
Geetika Khanna, MD,
"Evidence based imaging of
scoliosis."
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SYMPOSIA
Continued from page 31
William McAllister, MD,
"Osteoprotegerin (OPG) deficiency mimicked by a novel
15-base pair tandem duplication in TNFRSF11A encoding
RANK: merging the juvenile
Paget's disease and expansile
skeletal hyperphosphatasia
phenotypes"; C.1250>G,
p.N417S is a common American TNSALP mutation
involved in all clinical forms
of hypophosphatasia (HPP),
including pseudo-HPP."

AMERICAN ROENTGEN
RAY SOCIETY
109"' Annual Meeting
Boston, Massachusetts
April 26-May 1,2009

REVIEW COURSES

Alumni News
Within a two-month period,
Bruce McClennan, MD, former
chief of Mallinckrodt Institute's
Abdominal Imaging section,
received two Gold Medal
awards: the first from the Society of Uroradiology, the other
from the American Roentgen
Ray Society (ARRS). He is a
professor of radiology at Yale
University and a former chair of
Yale's Department of Diagnostic Radiology.

John Crowe, MD, 2008-2009 ARRS president, and (left) McClennan at the Gold Medal Award ceremony at the Society's
109th Annual Meeting in Boston.

Sanjeev Bhalla, MD,
Course director, "Approach
to diagnosis: a case-based
imaging review."

Christine Menias, MD,
"Gastrointestinal imaging:
esophagus, stomach, small
bowel."

Sanjeev Bhalla, MD,
"Cardiovascular imaging:
plain film correlates of cardiovascular disease."

Christine Menias, MD,
"Acute intestinal ischemia
and bleeding."
Pamela Woodard, MD,
moderator, "Cardiopulmonary imaging papers."

Sanjeev Bhalla, MD, "CTA
of the thorax: pulmonary
thromboembolic disease,
arterial and venous malformations, acute aortic syndromes and postoperative
evaluation of the aorta."

Pamela Woodard, MD,
keynote, "Cardiac imaging:
2009 update."

Cylen Javidan-Nejad, MD,
"Cardiovascular imaging:
chest pain."

Cylen Javidan-Nejad, MD,
"Truths and myths of CTguided thoracic biopsies: factors affecting complications."

Christine Menias, MD,
moderator/'Genitourinary/
OB/GYN (pelvis) imaging
papers."
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SCIENTIFIC SESSIONS

Cylen Javidan-Nejad, MD;
Thomas Pilgram, PhD,
"CT-guided thoracic biopsies:
a five-year retrospective study
of outcomes."

EXHIBITS
Kartikeya Kantawala, MD;
Kathryn Robinson, MD;
Nirvikar Dahiya, MD;
William Middleton, MD;
Christine Menias, MD,
"Liver involvement in hereditary hemorrhagic telangiectasia: a multimodality
approach using CT, MR and
color Doppler sonography."

Kartikeya Kantawala, MD;
Nirvikar Dahiya, MD;
Kathryn Robinson, MD;
William Middleton, MD;
Sharlene Teefey, MD,
"Virtual cystoscopy using
three-dimensional ultrasound: a new dimension in
the evaluation of urinary
bladder pathologies."
Christine Menias, MD,
"Recent imaging and
interpretation advances
in diagnostic workup of
ovarian cystic lesions."

Editor's Note: On page 5 of the Winter 2008/2009
Focal Spot, Volume 39, Number 3, a Certificate of
Merit notation should have been shown for this poster
presentation: Geetika Khanna, MD; Takashi Sato; Polly
Ferguson, MD, "Chronic recurrent multifocal
osteomyelitis: a pictorial review."
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BJC INSTITUTE OF HEALTH

Construction of the BJC Institute of Health at Washington University is
nearing its targeted completion date of December 2009. The 700,000
square-foot building at the southwest corner of Euclid Avenue and Children's Place will serve as home base for Washington University's BioMed
21 initiative to establish a multidisciplinary research environment for the
acceleration of scientific discovery into clinical care.
Photograph by Kimberly Kama.
An artist's rendering of the completed project.
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